Skip to content
DataLookout
Menu

NCT07944690

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
Timeframe: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The maximum tolerated dose (MTD) of HLX49
Timeframe: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
RP2D
Timeframe: Approximately up to 24 months.
Objective response rate (ORR) assessed by IRRC
Timeframe: Approximately up to 24 months.

Secondary (9)

Objective response rate (ORR)
Duration of response (DOR)
Progression-free survival (PFS)
Overall survival (OS)
Cmax
Show 4 moreShow less
Tmax
T1/2
ADA (anti-drug antibody)
NAb (neutralizing antibody)

Arms and interventions

Ia (Dose Escalation)Experimental

Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.

Ib HLX49 Dose 1 (Dose Expansion)Experimental

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Ib HLX49 Dose 2 (Dose Expansion)Experimental

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Ib HLX49 Dose 3 (Dose Expansion)Experimental

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Ib Trastuzumab deruxtecan (Dose Expansion)Active comparator

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Drugs: HLX49, Trastuzumab Deruxtecan for Injection (T-DXd)

Sites

2 sites in 2 countries

Australia 1, China 1